Bioengineered corneal tissue for minimally invasive vision restoration in advanced keratoconus in two clinical cohorts

Visual impairment from corneal stromal disease affects millions worldwide. We describe a cell-free engineered corneal tissue, bioengineered porcine construct, double crosslinked (BPCDX) and a minimally invasive surgical method for its implantation. In a pilot feasibility study in India and Iran (cli...

Full description

Saved in:
Bibliographic Details
Published inNature biotechnology Vol. 41; no. 1; pp. 70 - 81
Main Authors Rafat, Mehrdad, Jabbarvand, Mahmoud, Sharma, Namrata, Xeroudaki, Maria, Tabe, Shideh, Omrani, Raha, Thangavelu, Muthukumar, Mukwaya, Anthony, Fagerholm, Per, Lennikov, Anton, Askarizadeh, Farshad, Lagali, Neil
Format Journal Article
LanguageEnglish
Published New York Nature Publishing Group US 01.01.2023
Nature Publishing Group
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Visual impairment from corneal stromal disease affects millions worldwide. We describe a cell-free engineered corneal tissue, bioengineered porcine construct, double crosslinked (BPCDX) and a minimally invasive surgical method for its implantation. In a pilot feasibility study in India and Iran (clinicaltrials.gov no. NCT04653922 ), we implanted BPCDX in 20 advanced keratoconus subjects to reshape the native corneal stroma without removing existing tissue or using sutures. During 24 months of follow-up, no adverse event was observed. We document improvements in corneal thickness (mean increase of 209 ± 18 µm in India, 285 ± 99 µm in Iran), maximum keratometry (mean decrease of 13.9 ± 7.9 D in India and 11.2 ± 8.9 D in Iran) and visual acuity (to a mean contact-lens-corrected acuity of 20/26 in India and spectacle-corrected acuity of 20/58 in Iran). Fourteen of 14 initially blind subjects had a final mean best-corrected vision (spectacle or contact lens) of 20/36 and restored tolerance to contact lens wear. This work demonstrates restoration of vision using an approach that is potentially equally effective, safer, simpler and more broadly available than donor cornea transplantation. A bioengineered cornea made of collagen restores vision in a pilot clinical study.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:1087-0156
1546-1696
1546-1696
DOI:10.1038/s41587-022-01408-w